Thursday, April 18, 2013
Medicago Inc., of Quebec City, and the Infectious Disease Research Institute (IDRI) in Seattle reported interim results from a Phase I trial testing an H5N1 avian influenza virus-like particle vaccine candidate, showing that it was safe and well tolerated and induced a solid immune response exceeding the three Committee for Medicinal Products for Human Use immunogenicity criteria for licensure of influenza vaccines.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.